Eisai 483 Handed Form 483 after Investigators Cite Control Records, CAPA Procedures

Drug Industry Daily
A A
The FDA has served drug manufacturer Eisai Inc. with a Form 483 after an investigation revealed laboratory control issues and incomplete records.

To View This Article:

Login

Subscribe To Drug Industry Daily